Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Daclizumab (anti-CD25) in multiple sclerosis.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.

Pages